Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1)
This study is currently recruiting participants.
Verified May 2013 by Exelixis
Study NCT01605227
Information provided by Exelixis
First Received on May 22, 2012.
Last Updated on May 2, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
